Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab

Ipilimumab and nivolumab are human monoclonal antibodies used in cancer therapy. Ipilimumab targets cytotoxic T-lymphocyte-associated antigen and nivolumab acts against programmed death receptor-1. Both drugs have extensive side effect profiles with high rates of cutaneous involvement. We present a...

Full description

Bibliographic Details
Main Authors: Shelby L Kubicki, Macartney E Welborn, Anisha B Patel
Format: Article
Language:English
Published: Innovative Healthcare Institute 2018-10-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
drug rash
immunotherapy
ipilimumab
nivolumab
toxic epidermal necrolysis
Online Access:https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_7_18

Internet

https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_7_18

Similar Items